Department of Clinical of Biochemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. CONICET.
Objectives: In acromegalic patients, cardiovascular and metabolic co-morbidities contribute to enhance mortality. Available data on the lipoprotein profile of these patients are controversial. Our aim was to characterize the lipoprotein profile and emergent biomarkers of cardiovascular disease in active acromegalic patients in comparison with sex- and age-matched healthy controls. Patients: Eighteen patients with active acromegaly and eighteen controls were studied. Measurements: Glucose levels, hormonal status, lipoprotein profile and C reactive protein (CRP) were evaluated by standardized methods. Cholesteryl ester transfer protein (CETP) and lipoprotein-associated phospholipase A(2 )(Lp-PLA(2)) were measured by radiometric techniques, endothelin-1 and vascular cell adhesion molecule (VCAM)-1 by enzyme-linked immunosorbent assay, and leukocytes CD18, CD49d and CD54 by flow cytometry. Results: After adjusting for body mass index (BMI), acromegalic patients presented a more atherogenic lipoprotein profile, consisting of higher levels of triglycerides and apolipoprotein B and alterations in the ratios which estimate insulin resistance and atherogenic risk. CETP activity was significantly increased in acromegalic patients as compared to controls (168+/-17 vs. 141+/-30 %/ml.h, respectively; p<0.05). Endothelin-1 levels evidenced an increase in the patients’ group (0.9+/-0.2 vs. 0.7+/-0.2 pg/ml; respectively; p<0.01) and showed positive and significant correlations with GH, IGF-1 and IGFBP-3 (r = 0.45, 0.42, and 0.44; respectively; p<0.01 for all of them; with BMI as a fixed variable). Lymphocytes from acromegalic patients showed increased CD49d content (282+/-59 vs. 246+/-48 arbitrary units; respectively; p<0.05). Conclusions: Taken together, the alterations described seem to contribute to constituting a state of higher propensity for the development of atherosclerotic cardiovascular disease, which adds to the presence of specific cardiomyopathy
https://bioalpha.com.ar/wp-content/uploads/2017/03/leuko4.jpg16001600c0380364/wp-content/uploads/2017/02/banners-bioalpha-06-1-300x80.pngc03803642008-06-08 14:44:362019-04-17 18:37:19Alterations in biomarkers of cardiovascular disease in active acromegaly.